<DOC>
	<DOCNO>NCT00005951</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness irinotecan plus temozolomide treating patient recurrent primary malignant glioma .</brief_summary>
	<brief_title>Irinotecan Plus Temozolomide Treating Patients With Recurrent Primary Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose irinotecan administer combination temozolomide patient recurrent primary malignant glioma . - Determine toxicity combination therapy patient . OUTLINE : This dose escalation study irinotecan . Patients stratify accord concurrent anticonvulsant ( Dilantin , Tegretol , phenobarbital v anticonvulsant none ) . Patients receive irinotecan IV 90 minute day 1 , 8 , 15 , 22 oral temozolomide day 1-5 . Treatment continue every 43 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent primary malignant glioma Anaplastic astrocytoma Glioblastoma multiforme Anaplastic oligodendroglioma Gliosarcoma Anaplastic mixed oligoastrocytoma Measurable disease MRI CT No immediate radiotherapy require Neurologically stable least 2 week prior study PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Greater 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN Alkaline phosphatase less 2 time ULN Renal : Blood urea nitrogen creatinine less 1.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No nonmalignant systemic disease No acute infection treat IV antibiotic No frequent vomit condition would preclude oral medication administration ( e.g. , partial bowel obstruction ) No prior malignancy except surgically cure carcinoma situ cervix basal squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior biologic therapy regimen Chemotherapy : No 1 prior chemotherapy regimen At least 6 week since prior chemotherapy , unless evidence disease progression No prior failure irinotecan temozolomide Endocrine therapy : Concurrent corticosteroid allow Radiotherapy : See Disease Characteristics At least 6 week since prior radiotherapy , unless evidence disease progression Surgery : At least 3 week since prior surgery , unless evidence disease progression , recover Other : No concurrent immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>